Compare GLND & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLND | KLRS |
|---|---|---|
| Founded | N/A | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.0M | 92.8M |
| IPO Year | 2026 | 2020 |
| Metric | GLND | KLRS |
|---|---|---|
| Price | $3.90 | $2.13 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $18.71 |
| AVG Volume (30 Days) | ★ 25.6M | 82.7K |
| Earning Date | 11-18-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $165,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.09 | $2.20 |
| 52 Week High | $12.80 | $11.88 |
| Indicator | GLND | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 58.64 | 16.83 |
| Support Level | $2.60 | N/A |
| Resistance Level | $6.69 | $4.37 |
| Average True Range (ATR) | 0.82 | 0.19 |
| MACD | -0.14 | -0.04 |
| Stochastic Oscillator | 36.47 | 1.02 |
Greenland Energy Co is a Texas energy resources company focused on unlocking Greenland's vast hydrocarbon potential through the application of modern exploration technologies. It holds exclusive licenses to over 2-million acre area in the Jameson Land Basin, where its licenses cover the majority of the basin. The business model for the company is based on exploration and resource development in the frontier basins of Greenland. The company's primary focus is drilling the first wells on the project to conduct the necessary exploration, appraisal and evaluation.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.